We performed a meta-analysis of the association of transforming growth factor α gene (TGFA) polymorphisms with the risk of cleft lip with or without cleft palate (CL/P) or cleft palate (CP). In total, data from 29 studies were pooled for the following 3 polymorphisms: TGFA/TaqI, TGFA/BamHI, and TGFA/RasI in the TGFA gene. A fixed-effects or random-effects model was used to calculate the pooled odds ratios based on the results from the heterogeneity tests. A significantly increased CL/P or CP risk was observed in persons carrying a C2 allele at the TaqI polymorphism (odds ratio (OR) = 1.70, 95% confidence interval (CI): 1.41, 2.05) compared with those with a C1 allele (OR = 1.57, 95% CI: 1.23, 2.01). For the TGFA/BamHI polymorphism, carriers of the minor A1 allele had an estimated relative decrease in CL/P risk (OR = 0.44, 95% CI: 0.30, 0.64). These associations remained significant when only high-quality studies were included. However, no significant association was observed between the TGFA/RasI variant and CL/P risk. In summary, this meta-analysis provided a robust estimate of the positive association of the TGFA/TaqI polymorphism with both CL/P and CP and suggests that persons with an A1 allele may have a markedly decreased risk of CL/P. cleft lip with or without cleft palate;
CL/P or CP, including TGFA (5-7), interferon regulatory factor 6 gene (IRF6) (8, 9) , bone morphogenetic protein 4 gene (BMP4) (10, 11) , and methylenetetrahydrofolate reductase gene (MTHFR) (12, 13) . Transforming growth factor α, encoded by a gene mapped at 2p13, is a secretion protein that binds to the epidermal growth factor receptor and is located at the palate epithelium during palate closure (5, 14, 15) . In mouse palatal shelf cultures, transforming growth factor α promotes the synthesis of extracellular matrix and mesenchymal cell migration and ensures the strength of the fused palate, suggesting that transforming growth factor α plays an important role in mouse palatal development (16) . The TGFA gene shows a restriction fragment length polymorphism when treated with TaqI, BamHI, or RasI restriction enzyme, which may contribute to nonsyndromic CL/P and CP.
To date, studies have focused on the association between the TGFA variant and OFC risk; however, results have been inconclusive, possibly because of inadequate sample sizes. Therefore, we conducted a meta-analysis to quantitatively assess the effect of the 3 polymorphisms in TGFA on the risk of nonsyndromic CL/P and CP.
MATERIALS AND METHODS

Publication search
Electronic searches in the Medline, Embase, China National Knowledge Infrastructure (http://www.global.cnki.net), and Chinese Biomedicine (http://www.sinomed.ac.cn) databases were performed by using the following search terms: ("cleft lip," "cleft palate," or "oral cleft"), ("polymorphism" or "variant"), and ("transforming growth factor alpha" or "TGFA"). The search was last performed in May 2013. In addition, the reference lists of reviews and retrieved articles were checked for additional potential studies. Articles that reported results from more than 1 population were considered as separate studies. Only studies published in English or Chinese were included. The studies included in the meta-analysis had to meet the following criteria: 1) case-control or cohort design, 2) association between TGFA polymorphisms (TGFA/TaqI, TGFA/ BamHI, or TGFA/RasI) and nonsyndromic CL/P or CP risk, and 3) sufficient genotype distribution for calculation of odds ratios with 95% confidence intervals. Articles were excluded if they overlapped with other studies, did not provide enough information on genotype frequency, or were abstracts, commentaries, or reviews.
Data extraction
The following data were extracted independently from each study by 2 authors: year of publication, name of first author, country of origin, ethnicity of the individuals involved (Caucasian, Asian, African, or mixed), source of controls, numbers of cases and controls, and number of genotypes in cases and controls. If the article did not provide sufficient information on genotype distribution, the original author was contacted for the detailed data. In addition, disagreements were resolved by discussion between the 2 investigators.
Quality score assessment
The quality of each study was independently assessed by 2 authors who used quality scoring criteria modified from previous meta-analyses (17-20) (Web Table 1 , available at http:// aje.oxfordjournals.org/). These scores were based on both traditional epidemiologic considerations and genetic issues. Quality scores ranged from 0 points (worst) to 11 points (best). Studies scoring less than 7 points were classified as low quality, and those scoring 7 points or higher were classified as high quality.
Statistical methods
The Hardy-Weinberg equilibrium (HWE) of the control group was assessed, and a P value of less than 0.05 was considered significant disequilibrium. The strength of the association between TGFA polymorphisms and CL/P or CP risk was evaluated by odds ratios with 95% confidence intervals. For the TGFA/TaqI polymorphism, the pooled odds ratios were estimated for C2 versus C1, C2C2 versus C1C1, C2C1 versus C1C1, the dominant model (C2C2 + C2C1 vs. C1C1), and the recessive model (C2C2 vs. C2C1 + C1C1). These genetic models were also assessed in the TGFA/BamHI and TGFA/RasI variants. Moreover, subgroup analysis was performed, when feasible, according to ethnicity, source of controls, date of publication, and sample size.
Heterogeneity was assessed by the χ 2 -based Q test and I 2 test (21) . A random-effects model was used when the P value for heterogeneity was less than 0.10 or I 2 was greater than 50%; otherwise, a fixed-effects model was used. Further, Galbraith plots were used to visualize the impact of individual studies on the overall homogeneity, which identified the outliers as possible major sources of heterogeneity (22) (23) (24) . Cumulative meta-analyses of associations for each polymorphism were also performed to investigate the trend and the stability of risk effect as evidence accumulated over time (by publication year). In addition, sensitivity analysis was carried out to evaluate the stability of the results through sequential removal of each study or after excluding those studies that deviated from HWE. Moreover, sensitivity analyses limited to only the high-quality studies or English-language studies were conducted to investigate the influence of low-quality studies or Chinese-language studies on the overall meta-analysis. Begg's funnel plots (25) and the Egger's test (26) were used to analyze publication bias; P values of less than 0.05 from the Egger's test were considered statistically significant. All statistical analyses were performed by using Stata, version 12, software, (StataCorp LP, College Station, Texas).
RESULTS
Characteristics of the included studies
After a preliminary screening, a total of 33 publications met the inclusion criteria. Nine of these studies were excluded after further scrutiny because 2 studies (15, 27) had no controls, 1 study (28) involved genotype distributions of parents only, and 6 studies (29-34) did not include genotype distributions. In 3 of the remaining 24 studies, the genotype distributions were sorted separately by ethnicity. Beaty et al. (35) reported separate data for those of African and Caucasian ethnicities; Sassani et al. (36) reported separate data for those of Asian, African, and Caucasian ethnicities; Shaw et al. (37) reported separate data by African, Caucasian, and "other" ethnicities. Thus, a total of 24 eligible publications (5, 7, 35-56), which reported on 29 studies, were included in the present meta-analysis. Among these studies, 27 investigated the association of the TGFA/TaqI variant with CL/P risk, and 12 investigated the association of the TGFA/TaqI variant with CP risk; 5 examined the association of the TGFA/BamHI variant with CL/P risk; and 5 examined the association of the TGFA/RasI polymorphism with CL/P risk. A total of 19 studies reported on Caucasian populations, 15 on Asian populations, 5 on African populations, 6 on mixed populations, and 4 on populations of "other" ethnicity. The distributions of genotypes in the control groups of all studies except 4 were in HWE (45, 46, 49, 53) . The flowchart Abbreviations: CL/P, cleft lip with or without cleft palate; HB, hospital-based; HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency; PB, population-based; TGFA, transforming growth factor α gene.
a All studies were of cleft lip with or without cleft palate and were published in English. b Quality scores ranged from 0 points (worst) to 11 points (best). Studies scoring less than 7 points were classified as low quality, and those scoring 7 points or higher were classified as high quality. Abbreviations: CL/P, cleft lip with or without cleft palate; HB, hospital-based; MAF, minor allele frequency; PB, population-based; TGFA, transforming growth factor α gene.
a All studies were of cleft lip with or without cleft palate and were published in English and there was Hardy-Weinberg equilibrium among all controls.
b Quality scores ranged from 0 points (worst) to 11 points (best). Studies scoring less than 7 points were classified as low quality, and those scoring 7 points or higher were classified as high quality. for the process of including/excluding articles is shown in Figure 1 , and the characteristics of all included studies are summarized in Tables 1-3 .
Association of the TGFA/TaqI polymorphism with CL/P risk A total of 27 studies examined the TGFA/TaqI variant and CL/P risk. The results of combined analyses revealed a significantly increased risk of CL/P for the genotype variant in all genetic models ( Figure 2 and Table 4 ). The odds ratio of 2.06 (95% confidence interval (CI): 1.38, 3.06) in carriers of 2 C2 alleles was higher than that in carriers of 1 C2 allele (odds ratio (OR) = 1.74, 95% CI: 1.46, 2.09). In the subgroup analysis by ethnicity, significantly increased risks were found among Caucasians for C2 versus C1, C2C1 versus C1C1, and the dominant model. Moreover, in Asian populations, significant correlation was observed in all genetic models. However, no association was detected in African and mixed population groups in any genetic models. Additionally, significantly elevated CL/P risks were observed in the hospital-based control group for all genetic models; however, in population-based groups, significant associations were found only in C2 versus C1, C2C1 versus C1C1, and the dominant model. Heterogeneity was observed in the following 3 models for the TGFA/TaqI polymorphism: C2 versus C1 (P = 0.004), C2C1 versus C1C1 (P = 0.01), and the dominant model (P = 0.005). The results of meta-regression analyses indicated that sample size could explain the τ 2 values in these genetic models (42.88%, P = 0.025; 47.00%, P = 0.018; and 45.92%, P = 0.019, respectively). Moreover, when combined with year, ethnicity and sample size could explain 83.14%, 95.54%, and 89.18% of the τ 2 values in the above 3 genetic models, respectively. When we analyzed data by subgroup, heterogeneity was removed in several groups, including Asian and mixed populations, studies with small sample size (<200 subjects), those with a mixed source of controls, and hospital-based groups ( Abbreviations: CI, confidence interval; CL/P, cleft lip with or without cleft palate; HB, hospital-based; HWE, Hardy-Weinberg equilibrium; OR, odds ratio; PB, population-based; TGFA, transforming growth factor α gene. a A random-effects model was used when the P value for heterogeneity was less than 0.10; otherwise, a fixed-effects model was used. b Quality scores ranged from 0 points (worst) to 11 points (best). Studies scoring less than 7 points were classified as low quality, and those scoring 7 points or higher were classified as high quality.
(Web Figure 1) ; the heterogeneity was effectively removed and the association was still significant after exclusion of these 4 studies (for C2 vs. C1, OR = 1.76, 95% CI: 1.54, 2.02, P for heterogeneity = 0.658; for C2C1 vs. C1C1, OR = 1.80, 95% CI: 1.54, 2.09, P for heterogeneity = 0.67; and for C2C2 + C2C1 vs. C1C1, OR = 1.83, 95% CI: 1.58, 2.13, P for heterogeneity = 0.62). Sensitivity analysis also showed that no single study qualitatively changed the pooled odds ratios, indicating that the results of this meta-analysis are highly stable (Figure 3) . It was noted that the correlation between the TGFA/TaqI polymorphism and CL/P risk remained significant after low-quality studies were excluded. After exclusion of Chinese-language studies, the pooled odds ratio did not change. Moreover, there were 2 studies (42, 46) that deviated from HWE for the TGFA/TaqI variant; when these were excluded, the estimated pooled odds ratio did not change at all. Cumulative meta-analysis for the TGFA/TaqI polymorphism was conducted by publication date. The resulting pooled odds ratios tended to be stable with the accumulation of more data over time (Web Figure 2A) .
Association between the TGFA/TaqI polymorphism and CP
Twelve eligible studies were used to investigate the association between the TGFA/TaqI variant and CP risk. The contribution of the TGFA/TaqI variant to CP risk was observed in the C2 versus C1 (Web Figure 3) heterozygote comparison and the dominant model in the entire population, as well as among Asian and Caucasian populations (Table 5 ). However, no association was found in African-only populations. When stratified by source of control, a significant elevated CP risk was associated with the TGFA/TaqI polymorphism in hospital-based control groups, but not among populationbased control groups. No heterogeneity was detected in any genetic model. Sensitivity analysis showed that a significantly increased CP risk was observed (for C2C2 vs. C1C1, OR = 2.99, 95% CI: 1.12, 7.99; for the dominant model, OR = 2.73, 95% CI: 1.02, 7.26) after removal of 1 study (43) . The association was still significant after the removal of low-quality studies or Chinese-language studies. When excluding the study departing from HWE (42), the pooled odds ratios did not change. Cumulative meta-analysis indicated that pooled odds ratios tended to be stable with the accumulation of more data over time (Web Figure 2B) .
Association of the TGFA/BamHI and TGFA/RasI polymorphisms with CL/P risk Five studies each were included for the TGFA/BamHI and TGFA/RasI polymorphisms. A significantly decreased risk of CL/P was associated with the TGFA/BamHI polymorphism in 3 genetic models (A1 vs. A2, A1A2 vs. A2A2, and the recessive model) ( Table 6 and Web Figure 4) . Similar results were observed in the subgroups of Caucasians and mixed populations. After exclusion of the low-quality studies or those deviating from HWE, the pooled odds ratios did not change. However, for the TGFA/RasI polymorphism, no associations were detected in any genetic model or in the subgroup analysis by ethnicity (Table 7 and Figure 4 ). There was no significant heterogeneity among these studies.
Publication bias. Egger's test and Begg's funnel plot were used to evaluate potential publication bias in the 3 polymorphisms for all genetic models. No evidence of publication bias was observed for the 3 polymorphisms, indicating that our results are statistically robust. Figure 5 shows a funnel plot that examined the TGFA/TaqI polymorphism and risk of OFC.
DISCUSSION
OFCs are the most common craniofacial birth defects in humans, with an average worldwide prevalence of 1.2 per 1,000 births. Transforming growth factor α, an epidermal growth factor receptor ligand made by most epithelia, is expressed more intensely in regions of the developing primary palate and plays a role in cell proliferation during morphogenesis of the primary palate. Moreover, in mouse palatal cultures, transforming growth factor α promotes the synthesis of extracellular matrix and ensures the strength of the fused palate (14, 16, 57) . Recently, although TGFA polymorphisms were reported to contribute to the increased risk of OFCs in 1 or more early studies, few of those findings were consistently positive across all studies (5, 7, 39, 40, 44) , primarily because of a lack of adequate sample size. Therefore, we conducted a meta-analysis of 29 case-control studies to investigate whether TGFA variants (TGFA/TaqI, TGFA/BamHI, and TGFA/RasI) are risk factors for CL/P or CP.
The evidence regarding the association between TGFA/ TaqI polymorphisms and CL/P was considered inconclusive in the first meta-analysis (58). Ioannidis et al. (59) found a small but significant effect of the TGFA/TaqI variant on CL/P risk. The results from a meta-analysis of genome scans for the 2p13 region resulted in a P value of 0.001, but did not reach genome-wide significance, which would have been indicated by a P value of 0.0004 (60) . The main reason for the conflicting results may have been the lack of power to detect very mild effects (61) . In the present metaanslysis, for the analysis of the TGFA/TaqI variant, a significantly increased CL/P risk was observed in all genetic models. When the data were stratified by ethnicity, no A random-effects model was used when the P value for heterogeneity was less than 0.10; otherwise, a fix-effects model was used.
b Quality scores ranged from 0 points (worst) to 11 points (best). Studies scoring less than 7 points were classified as low quality, and those scoring 7 points or higher were classified as high quality.
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Downloaded from https://academic.oup.com/aje/article-abstract/179/3/267/103584 by guest on 13 January 2019 Abbreviations: CI, confidence interval; CL/P, cleft lip with or without cleft palate; OR, odds ratio; TGFA, transforming growth factor α gene. a A random-effects model was used when the P value for heterogeneity was less than 0.10; otherwise, a fix-effects model was used. b Quality scores ranged from 0 points (worst) to 11 points (best). Studies scoring less than 7 points were classified as low quality, and those scoring 7 points or higher were classified as high quality. Abbreviations: CI, confidence interval; CL/P, cleft lip with or without cleft palate; HWE, Hardy-Weinberg equilibrium; OR, odds ratio; TGFA, transforming growth factor α gene. a A random-effects model was used when the P value for heterogeneity was less than 0.10; otherwise, a fixed-effects model was used. b Quality scores ranged from 0 points (worst) to 11 points (best). Studies scoring less than 7 points were classified as low quality, and those scoring 7 points or higher were classified as high quality. statistical correlation was found in African and mixed populations, suggesting that the relative contribution of individual susceptibility genes may vary across different populations, as previously described (1, 3, 6) . In general, European-derived populations have intermediate prevalence rates of OFCs of approximately 1/1,000. Compared with those of European ethnicity, Asians and American Indians have higher prevalence (1/500), and those of African descent have lower prevalence (1/2,500). In the population-based and mixed-base control studies, no significant correlation was observed in the homozygote comparison and the recessive model. A previous study indicated that heterogeneity existed between CL/P patients and was unlikely to be attributable to differences in their ethnic/racial composition (58) . In our study, significant heterogeneity existed when all 27 studies were pooled. However, Galbraith plot analyses indicated that 4 studies (39) (40) (41) 43) were the possible origin of heterogeneity; when we excluded these studies, the heterogeneity was removed. High percentages of patients with a family history of OFCs (40, 41) and ethnic heterogeneity (39) might explain some heterogeneity. In addition, we performed meta-regression and subgroup analyses. We found that the heterogeneity was remarkably decreased among hospital-based and mixed-base control groups, small samples (<200 subjects), and Asian and mixed populations, indicating that the source of control, sample size, and ethnicity may contribute to the heterogeneity. Results of meta-regression showed that, when combined, year, ethnicity, and sample size could explain nearly 90% of the τ 2 . In addition, the pooled odds ratio did not change in the sensitivity analysis that excluded studies that departed from HWE or Chinese-language studies, indicating that the results of this meta-analysis are highly stable. It is not uncommon for the quality of studies to vary in meta-analyses of genetic association studies (19) . In addition, subgroup analysis on high-quality studies may produce results that are different from the overall results (17, 20) . Therefore, we performed sensitivity analyses limited to only the high-quality studies to investigate the influence of low-quality studies on the overall meta-analysis. The results showed that the association between the TGFA/TaqI polymorphism and CL/P risk remained significant when only high-quality studies were included, suggesting our results are robust.
The TGFA/BamHI polymorphism showed significant association with CL/P risk in the allelic, A1A2 versus A2A2, and dominant models. In the subgroup analysis stratified by ethnicity, similar correlations were observed both in mixed and Caucasian populations. No between-study heterogeneity existed in any genetic models. Sensitivity analysis showed that no single study qualitatively changed the pooled odds ratios. Moreover, after exclusion of studies that departed from HWE, low-quality studies, or Chinese-language studies, the pooled odds ratio still did not change, demonstrating that the results of this meta-analysis are stable. For the TGFA/RasI variant, no statistical association was observed in any genetic models.
The lip and primary palate have distinct developmental origins from the secondary palate. Epidemiologic data across different populations have shown that families at high risk for 1 type of OFC are not at increased risk for the other type. Moreover, the prevalence of CP is generally lower than that of CL/P (62). Thus, CP may have different genetic causes and should, when feasible, be analyzed separately (63, 64) . Studies of the TGFA/TaqI polymorphism and CP risk showed no between-study heterogeneity. A markedly increased CP risk was associated with the C2 allele in 3 genetic models (C2 vs. C1, the heterozygote comparison, and the dominant model) in the entire population, as well as in mixed and Caucasian populations. C2 was associated with a significantly increased CL/P risk in hospital-based studies, but not in populationbased studies. However, the genotype distribution in hospital-based studies may not be representative of the general population. Therefore, the pooled result for the TGFA/ BamHI variant may be a spurious finding, and larger, population-based studies are required to further clarify the association between the TGFA/BamHI polymorphism and CL/P risk.
Several limitations of our study should be considered. First, we did not include studies that contained only the allele frequency. Among these, 2 studies (32, 34) showed a positive association with CL/P, and the others (29) (30) (31) 33) suggested no association with CL/P. Second, publication bias might be possible because only published studies were retrieved in the meta-analysis, even though the funnel plot and Egger's tests did not show it. Third, because only studies published in Chinese and English were included, a language bias may have been introduced. Also, maternal smoking during pregnancy has been linked consistently with increased risks of both CL/P and CP, with a population-attributable risk as high as 20% (3, 65, 66) . However, we could not take maternal smoking into account because of a lack of sufficient data. Finally, CL/P is a complex disorder, and a likely scenario is that variation in more than 1 gene underlies nonsyndromic CL/P. A recent report showed that gene-gene interaction of TGFA and IRF6 could account for 1% to as much as 10% of CL/P cases (67). However, such gene-gene interactions were not addressed in this meta-analysis because of a lack of sufficient data.
Despite these limitations, our results were significant. The results of this meta-analysis suggest that the C2 allele at TGFA/TaqI is a risk factor for both CL/P and CP, especially in Asian populations. Moreover, the A1 allele at TGFA/ BamHI was a protective factor for CL/P. However, no association was observed between the TGFA/RasI polymorphism and CL/P risk. Future studies are needed to investigate genematernal smoking and gene-gene interactions. Moreover, studies of the TGFA/BamHI polymorphism in different populations with larger sample sizes are needed. There is an important role for studies that include animal disease modeling to identify the exact role of TGFA polymorphisms in the pathogenesis of OFCs.
